BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

213 related articles for article (PubMed ID: 7783568)

  • 1. P-glycoprotein-mediated multidrug resistance in tumor cells: biochemistry, clinical relevance and modulation.
    Shustik C; Dalton W; Gros P
    Mol Aspects Med; 1995; 16(1):1-78. PubMed ID: 7783568
    [No Abstract]   [Full Text] [Related]  

  • 2. The role of P-glycoprotein in drug resistance in multiple myeloma.
    Abraham J; Salama NN; Azab AK
    Leuk Lymphoma; 2015 Jan; 56(1):26-33. PubMed ID: 24678978
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Using purified P-glycoprotein to understand multidrug resistance.
    Shapiro AB; Ling V
    J Bioenerg Biomembr; 1995 Feb; 27(1):7-13. PubMed ID: 7629053
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lapatinib (Tykerb, GW572016) reverses multidrug resistance in cancer cells by inhibiting the activity of ATP-binding cassette subfamily B member 1 and G member 2.
    Dai CL; Tiwari AK; Wu CP; Su XD; Wang SR; Liu DG; Ashby CR; Huang Y; Robey RW; Liang YJ; Chen LM; Shi CJ; Ambudkar SV; Chen ZS; Fu LW
    Cancer Res; 2008 Oct; 68(19):7905-14. PubMed ID: 18829547
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical impact of multidrug resistance in acute leukemia.
    Dutcher JP; Wiernik PH
    Leuk Res; 2002 Mar; 26(3):323-5. PubMed ID: 11792423
    [No Abstract]   [Full Text] [Related]  

  • 6. Multidrug resistance: clinical relevance in haematological malignancies.
    Kaye SB; Kerr DJ
    Blood Rev; 1991 Mar; 5(1):38-41. PubMed ID: 1674435
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Modulation of multidrug resistance in multiple myeloma.
    Sonneveld P
    Baillieres Clin Haematol; 1995 Dec; 8(4):831-44. PubMed ID: 8845575
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Characterization and functional reconstitution of the multidrug transporter.
    Sharom FJ
    J Bioenerg Biomembr; 1995 Feb; 27(1):15-22. PubMed ID: 7629046
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The P-glycoprotein multidrug transporter: interactions with membrane lipids, and their modulation of activity.
    Sharom FJ
    Biochem Soc Trans; 1997 Aug; 25(3):1088-96. PubMed ID: 9388605
    [No Abstract]   [Full Text] [Related]  

  • 10. In vitro models of multiple drug resistance.
    Greenberger LM; Cohen D; Horwitz SB
    Cancer Treat Res; 1994; 73():69-106. PubMed ID: 7710911
    [No Abstract]   [Full Text] [Related]  

  • 11. P-glycoprotein-mediated resistance to chemotherapy in cancer cells: using recombinant cytosolic domains to establish structure-function relationships.
    Di Pietro A; Dayan G; Conseil G; Steinfels E; Krell T; Trompier D; Baubichon-Cortay H; Jault J
    Braz J Med Biol Res; 1999 Aug; 32(8):925-39. PubMed ID: 10454753
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical relevance of P-glycoprotein expression in haematological malignancies.
    Nooter K; Sonneveld P
    Leuk Res; 1994 Apr; 18(4):233-43. PubMed ID: 7909572
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Multidrug resistance--a fascinating, clinically relevant problem in bioenergetics.
    Pedersen PL
    J Bioenerg Biomembr; 1995 Feb; 27(1):3-5. PubMed ID: 7629048
    [No Abstract]   [Full Text] [Related]  

  • 14. The role of P-glycoprotein in drug-resistant hematologic malignancies.
    Dalton WS; Grogan TM; Miller TP
    Cancer Treat Res; 1991; 57():187-208. PubMed ID: 1686717
    [No Abstract]   [Full Text] [Related]  

  • 15. Clinical reversal of multidrug resistance.
    Sikic BI; Fisher GA; Lum BL; Brophy NA; Yahanda AM; Adler KM; Halsey J
    Cancer Treat Res; 1994; 73():149-65. PubMed ID: 7710904
    [No Abstract]   [Full Text] [Related]  

  • 16. Multidrug resistance: genes, polymorphisms, biologic effects, reversal and treatment in cancer chemotherapy.
    Aragon-Ching JB
    Anticancer Agents Med Chem; 2010 Oct; 10(8):582. PubMed ID: 21244347
    [No Abstract]   [Full Text] [Related]  

  • 17. Cellular and biochemical characterization of VX-710 as a chemosensitizer: reversal of P-glycoprotein-mediated multidrug resistance in vitro.
    Germann UA; Shlyakhter D; Mason VS; Zelle RE; Duffy JP; Galullo V; Armistead DM; Saunders JO; Boger J; Harding MW
    Anticancer Drugs; 1997 Feb; 8(2):125-40. PubMed ID: 9073309
    [TBL] [Abstract][Full Text] [Related]  

  • 18. P-glycoprotein--a mediator of multidrug resistance in tumour cells.
    Germann UA
    Eur J Cancer; 1996 Jun; 32A(6):927-44. PubMed ID: 8763334
    [No Abstract]   [Full Text] [Related]  

  • 19. New light on multidrug binding by an ATP-binding-cassette transporter.
    Shilling RA; Venter H; Velamakanni S; Bapna A; Woebking B; Shahi S; van Veen HW
    Trends Pharmacol Sci; 2006 Apr; 27(4):195-203. PubMed ID: 16545467
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Multidrug resistance (MDR) genes in haematological malignancies.
    Nooter K; Sonneveld P
    Cytotechnology; 1993; 12(1-3):213-30. PubMed ID: 7765326
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.